PortalPublikationenPredominance of high-grade pathway in breast cancer developm...

Predominance of high-grade pathway in breast cancer development of Middle East women.

Standard

Predominance of high-grade pathway in breast cancer development of Middle East women. / Al-Kuraya, Khawla; Schraml, Peter; Sheikh, Salwa; Amr, Samir; Torhorst, Joachim; Tapia, Coya; Novotny, Hedvika; Spichtin, Hanspeter; Maurer, Robert; Mirlacher, Martina; Simon, Ronald; Sauter, Guido.

in: MODERN PATHOL, Jahrgang 18, Nr. 7, 7, 2005, S. 891-897.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Al-Kuraya, K, Schraml, P, Sheikh, S, Amr, S, Torhorst, J, Tapia, C, Novotny, H, Spichtin, H, Maurer, R, Mirlacher, M, Simon, R & Sauter, G 2005, 'Predominance of high-grade pathway in breast cancer development of Middle East women.', MODERN PATHOL, Jg. 18, Nr. 7, 7, S. 891-897. <http://www.ncbi.nlm.nih.gov/pubmed/15803183?dopt=Citation>

APA

Al-Kuraya, K., Schraml, P., Sheikh, S., Amr, S., Torhorst, J., Tapia, C., Novotny, H., Spichtin, H., Maurer, R., Mirlacher, M., Simon, R., & Sauter, G. (2005). Predominance of high-grade pathway in breast cancer development of Middle East women. MODERN PATHOL, 18(7), 891-897. [7]. http://www.ncbi.nlm.nih.gov/pubmed/15803183?dopt=Citation

Vancouver

Al-Kuraya K, Schraml P, Sheikh S, Amr S, Torhorst J, Tapia C et al. Predominance of high-grade pathway in breast cancer development of Middle East women. MODERN PATHOL. 2005;18(7):891-897. 7.

Bibtex

@article{674690fe7cc74fe6b3f45c5ef5404e7a,
title = "Predominance of high-grade pathway in breast cancer development of Middle East women.",
abstract = "Recent data have suggested considerable molecular differences in cancers from various ethnical groups. As molecular features are increasingly used for predicting cancer prognosis and response to therapy, better knowledge of ethnic molecular features is important. To identify potential molecular differences between breast cancers in Europe and the Middle East, we analyzed consecutive breast cancer series from Switzerland (n=2197) and Saudi Arabia (n=204). Tissue microarrays were analyzed by fluorescence in situ hybridization for HER2, CCND1, MYC, and EGFR amplification. The data revealed marked differences between Saudi and Swiss patients. Saudi breast cancers had a markedly higher frequency of HER2 (31 vs 17%; P",
author = "Khawla Al-Kuraya and Peter Schraml and Salwa Sheikh and Samir Amr and Joachim Torhorst and Coya Tapia and Hedvika Novotny and Hanspeter Spichtin and Robert Maurer and Martina Mirlacher and Ronald Simon and Guido Sauter",
year = "2005",
language = "Deutsch",
volume = "18",
pages = "891--897",
journal = "MODERN PATHOL",
issn = "0893-3952",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Predominance of high-grade pathway in breast cancer development of Middle East women.

AU - Al-Kuraya, Khawla

AU - Schraml, Peter

AU - Sheikh, Salwa

AU - Amr, Samir

AU - Torhorst, Joachim

AU - Tapia, Coya

AU - Novotny, Hedvika

AU - Spichtin, Hanspeter

AU - Maurer, Robert

AU - Mirlacher, Martina

AU - Simon, Ronald

AU - Sauter, Guido

PY - 2005

Y1 - 2005

N2 - Recent data have suggested considerable molecular differences in cancers from various ethnical groups. As molecular features are increasingly used for predicting cancer prognosis and response to therapy, better knowledge of ethnic molecular features is important. To identify potential molecular differences between breast cancers in Europe and the Middle East, we analyzed consecutive breast cancer series from Switzerland (n=2197) and Saudi Arabia (n=204). Tissue microarrays were analyzed by fluorescence in situ hybridization for HER2, CCND1, MYC, and EGFR amplification. The data revealed marked differences between Saudi and Swiss patients. Saudi breast cancers had a markedly higher frequency of HER2 (31 vs 17%; P

AB - Recent data have suggested considerable molecular differences in cancers from various ethnical groups. As molecular features are increasingly used for predicting cancer prognosis and response to therapy, better knowledge of ethnic molecular features is important. To identify potential molecular differences between breast cancers in Europe and the Middle East, we analyzed consecutive breast cancer series from Switzerland (n=2197) and Saudi Arabia (n=204). Tissue microarrays were analyzed by fluorescence in situ hybridization for HER2, CCND1, MYC, and EGFR amplification. The data revealed marked differences between Saudi and Swiss patients. Saudi breast cancers had a markedly higher frequency of HER2 (31 vs 17%; P

M3 - SCORING: Zeitschriftenaufsatz

VL - 18

SP - 891

EP - 897

JO - MODERN PATHOL

JF - MODERN PATHOL

SN - 0893-3952

IS - 7

M1 - 7

ER -